WuXi AppTec’s small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego. STA provides Process R&D and API manufacturing services for early phase clinical studies.

“STA is a leading global Contract Development and Manufacturing Organization for innovative small molecule active pharmaceutical ingredients and advanced intermediates, from preclinical through commercial,” said Dr. Minzhang Chen, CEO of STA. “Our new U.S. based presence with a highly experienced scientific and production team is another step towards better enabling our partners through added capacity, greater flexibility, and our customer-centric approach to drug development and manufacturing services.” 

“WuXi’s open-access capability and technology platform strives to enable anyone and any company to discover and develop healthcare products more efficiently and cost effectively,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “This new facility further brings our comprehensive R&D services closer to our North American customers and partners in their efforts to improve patients’ lives.”

WuXi also has U.S. facilities in Cambridge, MA, Plainsboro, NJ, Philadelphia and Lansdale, PA, St. Paul, MN, Atlanta, GA and a global presence in Germany, Iceland, Israel, South Korea, and Japan. The company is headquartered in Shanghai with global footprint of more 6.0 million sq.-ft. of R&D space across 26 sites.